<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643707</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE Brady</org_study_id>
    <nct_id>NCT01643707</nct_id>
  </id_info>
  <brief_title>Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)</brief_title>
  <acronym>IMPROVE Brady</acronym>
  <official_title>Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is expected to provide evidence to support claim(s) that:&#xD;
&#xD;
        -  Education and process improvement initiatives can improve the diagnosis of and&#xD;
           appropriate therapy application for sinus node dysfunction (SND)&#xD;
&#xD;
        -  The quality improvement methods studied have general applicability and can be used by&#xD;
           all centers&#xD;
&#xD;
        -  Appropriate treatment minimizes caregiver burden&#xD;
&#xD;
        -  Appropriate treatment improves quality of life (QOL) and functional status compared to&#xD;
           pre-implant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention</measure>
    <time_frame>Up to 1 year post enrollment</time_frame>
    <description>The absolute change in the proportion of subjects diagnosed with SND before and after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Absolute Change in the Proportion of Subjects Receiving Indicated Therapy Before and After Intervention</measure>
    <time_frame>Up to 6 months post diagnosis</time_frame>
    <description>Outcome measure applies to subjects that receive a SND diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Phase I Subjects Diagnosed With SND and the Number of Diagnoses That Result in Indicated Therapy</measure>
    <time_frame>SND diagnosis assessed at 6 and 12 months of follow-up from enrollment until resulting IPG therapy</time_frame>
    <description>Enrolled subjects only with an SND diagnosis were reassessed at 6 and 12 months post enrollment were reassessed for IPG therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time to Diagnosis of SND Before and After Intervention</measure>
    <time_frame>From date of enrollment until date of SND diagnosis, assessed up to 60 months</time_frame>
    <description>Time to diagnosis days (date of diagnosis - date of enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time to Receiving an Indicated IPG Device for Subjects Diagnosed With SND Before and After Intervention</measure>
    <time_frame>From date of SND diagnosis until date of therapy, assessed up to 6 months</time_frame>
    <description>Time to implant in days (date of implant - date of diagnosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in QoL Between Implant Visit and 6 Months Post-implant</measure>
    <time_frame>between implant visit and 6 months post-implant</time_frame>
    <description>The difference in quality of life was assessed using the SF-12 survey, with higher numbers indicating a better quality of life for the patient. The possible physical score ranges are between 24.0 and 56.6. The possible mental score ranges are between 19.1 and 60.8. Only the difference over time was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Zarit Quality of Life (QOL) Between Implant Visit and 6 Months Post-implant</measure>
    <time_frame>between implant visit and 6 months post-implant</time_frame>
    <description>The difference in caregiver burden was assessed using a Zarit survey, with lower numbers indicating a decreased burden or a better outcome for the caregiver. The possible range of scores was between 0 and 88. Only the difference in scores over time were reported.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1342</enrollment>
  <condition>Sinus Node Dysfunction</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Evidence based guidelines and tools</intervention_name>
    <description>Education, guidelines, tools</description>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with possible sinus node dysfunction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is at least 18 years of age&#xD;
&#xD;
          -  Patient's heart rate meets at least one of the following:&#xD;
&#xD;
               -  Patient has a sinus rate ≤ 50 OR a junctional escape rhythm no faster than 50&#xD;
&#xD;
               -  Patient has a history of exercise intolerance&#xD;
&#xD;
          -  Patient complains of general fatigue, shortness of breath, shortness of breath with&#xD;
             exertion, syncope, light headed dizziness, palpitations, lethargy, dyspnea OR malaise&#xD;
             within the last 30 days that are not related to other discovered causes (such as&#xD;
             untreated hypothyroidism or anemia).&#xD;
&#xD;
          -  Patient (or patient's legally authorized representative) is willing and able to sign&#xD;
             and date written Patient Consent Form/Patient Data Release Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has type II 2nd degree AV block, High degree AV block (2:1, 3:1, 4:1 etc.) or&#xD;
             3rd degree AV block&#xD;
&#xD;
          -  Patient has recent history of blood loss&#xD;
&#xD;
          -  Patient has a medical history leading to suspicion of neurological disorder&#xD;
&#xD;
          -  Patient has a history of Chronic Atrial Fibrillation&#xD;
&#xD;
          -  Patient is enrolled or planning to participate in a concurrent drug and/or device&#xD;
             study at any time during the course of this clinical study without documented&#xD;
             pre-approval from the Medtronic study manager&#xD;
&#xD;
          -  Patient is not expected to survive for 12 months&#xD;
&#xD;
          -  Patient is anticipated to be unwilling or unable to comply with the clinical&#xD;
             investigation plan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Agudos</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Foundation Hospital and Research Institute</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital Limited</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Balaji Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>DL</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Insitute of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RajaRajeswari Medical College &amp; Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission Institute of Cardiovascular Diseases</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George's Medical University</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mission Hospital</name>
      <address>
        <city>Durgapur</city>
        <state>West Bengal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Devki Devi Heart and Vascular Institute</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional de Occidente IMSS</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Militar</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMAE Hospital de Cardiologia Centro Medico nacional Siglo XXI IMSS</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Carlos Alberto Seguín Escobedo</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Cardiovascular</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amur State Medical Academy</name>
      <address>
        <city>Amur</city>
        <state>Amur Oblast</state>
        <zip>675006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Federal Center of Cardiovascular Surgery</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Center of Cardio-Vascular Surgery</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Modern Cardiology</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa de Galicia</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bangladesh</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Uruguay</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sick Sinus Syndrome</keyword>
  <keyword>Bradycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01643707/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01643707/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Phase I served as a control period during which physicians assessed and treated subjects per their site's standard care practice. In Phase 2, investigators completed an educational workshop, were given access to the IMPROVE Brady toolkit and encouraged to adapt tools from this kit to create a practice-specific process improvement implementation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I</title>
          <description>Phase I served as a control period during which physicians assessed and treated subjects per their site's standard care practice.</description>
        </group>
        <group group_id="P2">
          <title>Phase II</title>
          <description>In Phase 2, investigators completed an educational workshop, were given access to the IMPROVE Brady toolkit and encouraged to adapt tools from this kit to create a practice-specific process improvement implementation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="858"/>
                <participants group_id="P2" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="823"/>
                <participants group_id="P2" count="470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Phase 1, the control phase, we expect to obtain baseline measurements for key variables including the rate of SND diagnosis and the rate of implantation of an IPG in subjects with an SND diagnosis.2nd phase, the experimental phase, patients will have scheduled follow-up to collect questionnaire data if they are implanted with an IPG.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I</title>
          <description>Phase I served as a control period during which physicians assessed and treated subjects per their site's standard care practice. Phase I of the study was to understand the current pathways at hospital for SND patient screening &amp; management.</description>
        </group>
        <group group_id="B2">
          <title>Phase II</title>
          <description>In Phase II, investigators completed an educational workshop, were given access to the IMPROVE Brady toolkit and encouraged to adapt tools from this kit to create a practice-specific process improvement implementation. The toolkit included: a physician training seminar, a diagnostic algorithm, patient education materials, a list of available therapy options, and/or information regarding the benefits and risks associated with the therapy options.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="823"/>
            <count group_id="B2" value="470"/>
            <count group_id="B3" value="1293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="16.0"/>
                    <measurement group_id="B2" value="57.9" spread="14.9"/>
                    <measurement group_id="B3" value="59.3" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="342"/>
                    <measurement group_id="B3" value="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnic Origin</title>
              <category_list>
                <category>
                  <title>Subject/Physician Chose not to provide information</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reportable per local laws or regulations</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="444"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="789"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Two or More Races</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention</title>
        <description>The absolute change in the proportion of subjects diagnosed with SND before and after intervention</description>
        <time_frame>Up to 1 year post enrollment</time_frame>
        <population>Only sites in South Asia participated in both Phase 1 and Phase 2, as such those subjects were included for objective analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1</title>
            <description>Control subjects in the South Asia Region.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2</title>
            <description>Treatment subjects in the South Asia Region</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention</title>
          <description>The absolute change in the proportion of subjects diagnosed with SND before and after intervention</description>
          <population>Only sites in South Asia participated in both Phase 1 and Phase 2, as such those subjects were included for objective analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A chi-square test was performed to determine a difference between Phase 1 and Phase 2.</non_inferiority_desc>
            <p_value>&lt;0.00001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Absolute Change in the Proportion of Subjects Receiving Indicated Therapy Before and After Intervention</title>
        <description>Outcome measure applies to subjects that receive a SND diagnosis</description>
        <time_frame>Up to 6 months post diagnosis</time_frame>
        <population>Subjects with an SND diagnosis</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1</title>
            <description>Control subjects in South Asia Region with an SND Diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Phase 2</title>
            <description>Treatment subjects in South Asia Region with an SND Diagnosis</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Change in the Proportion of Subjects Receiving Indicated Therapy Before and After Intervention</title>
          <description>Outcome measure applies to subjects that receive a SND diagnosis</description>
          <population>Subjects with an SND diagnosis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-Square test used to show any difference between Phase 1 and Phase 2</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Phase I Subjects Diagnosed With SND and the Number of Diagnoses That Result in Indicated Therapy</title>
        <description>Enrolled subjects only with an SND diagnosis were reassessed at 6 and 12 months post enrollment were reassessed for IPG therapy.</description>
        <time_frame>SND diagnosis assessed at 6 and 12 months of follow-up from enrollment until resulting IPG therapy</time_frame>
        <population>Only subjects diagnosed in each phase with SND.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1</title>
            <description>Control subjects in the South Asia Region.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2</title>
            <description>Treatment subjects in the South Asia Region</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Phase I Subjects Diagnosed With SND and the Number of Diagnoses That Result in Indicated Therapy</title>
          <description>Enrolled subjects only with an SND diagnosis were reassessed at 6 and 12 months post enrollment were reassessed for IPG therapy.</description>
          <population>Only subjects diagnosed in each phase with SND.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects Diagnosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Implanted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-Square test used to show any difference between Phase 1 and Phase 2</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This endpoint was covered in primary objective 2, so this analysis is the same as previously reported.</p_value_desc>
            <method>Chi-squared</method>
            <other_analysis_desc>See Primary Objectives for additional details.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Time to Diagnosis of SND Before and After Intervention</title>
        <description>Time to diagnosis days (date of diagnosis - date of enrollment)</description>
        <time_frame>From date of enrollment until date of SND diagnosis, assessed up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1</title>
            <description>Control subjects in South Asia Region with an SND Diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Phase 2</title>
            <description>Treatment subjects in South Asia Region with an SND Diagnosis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Time to Diagnosis of SND Before and After Intervention</title>
          <description>Time to diagnosis days (date of diagnosis - date of enrollment)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Months (or Prior to Enrollment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior to 1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Time to Receiving an Indicated IPG Device for Subjects Diagnosed With SND Before and After Intervention</title>
        <description>Time to implant in days (date of implant - date of diagnosis)</description>
        <time_frame>From date of SND diagnosis until date of therapy, assessed up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1</title>
            <description>Control subjects in South Asia Region with an SND Diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Phase 2</title>
            <description>Treatment subjects in South Asia Region with an SND Diagnosis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Time to Receiving an Indicated IPG Device for Subjects Diagnosed With SND Before and After Intervention</title>
          <description>Time to implant in days (date of implant - date of diagnosis)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Months or Prior to Implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior to 1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in QoL Between Implant Visit and 6 Months Post-implant</title>
        <description>The difference in quality of life was assessed using the SF-12 survey, with higher numbers indicating a better quality of life for the patient. The possible physical score ranges are between 24.0 and 56.6. The possible mental score ranges are between 19.1 and 60.8. Only the difference over time was reported.</description>
        <time_frame>between implant visit and 6 months post-implant</time_frame>
        <population>Only subjects receiving a Medtronic device with both Implant and 6 Month data were included</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 QoL Cohort</title>
            <description>Subjects with QoL scores at implant and 6 Months</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in QoL Between Implant Visit and 6 Months Post-implant</title>
          <description>The difference in quality of life was assessed using the SF-12 survey, with higher numbers indicating a better quality of life for the patient. The possible physical score ranges are between 24.0 and 56.6. The possible mental score ranges are between 19.1 and 60.8. Only the difference over time was reported.</description>
          <population>Only subjects receiving a Medtronic device with both Implant and 6 Month data were included</population>
          <units>difference of score on the SF-12 scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-12 Physical Component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 Mental Component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Zarit Quality of Life (QOL) Between Implant Visit and 6 Months Post-implant</title>
        <description>The difference in caregiver burden was assessed using a Zarit survey, with lower numbers indicating a decreased burden or a better outcome for the caregiver. The possible range of scores was between 0 and 88. Only the difference in scores over time were reported.</description>
        <time_frame>between implant visit and 6 months post-implant</time_frame>
        <population>Only subjects receiving a Medtronic device with both Implant and 6 Month data were included</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 QoL Cohort</title>
            <description>Subjects with QoL scores at implant and 6 Months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Zarit Quality of Life (QOL) Between Implant Visit and 6 Months Post-implant</title>
          <description>The difference in caregiver burden was assessed using a Zarit survey, with lower numbers indicating a decreased burden or a better outcome for the caregiver. The possible range of scores was between 0 and 88. Only the difference in scores over time were reported.</description>
          <population>Only subjects receiving a Medtronic device with both Implant and 6 Month data were included</population>
          <units>change in score on Zarit QoL scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration lasted 6 months</time_frame>
      <desc>Adverse events beyond death were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I</title>
          <description>Characterize the current management of patients presenting with possible sinus node dysfunction</description>
        </group>
        <group group_id="E2">
          <title>Phase II</title>
          <description>Assess the effect of critical care pathways, education and comprehensive disease state management on the adoption of ACC/AHA/HRS and ESC indications and therapies for sinus node dysfunction.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non-randomized observational study, data collected in a limited region with 10 specialized centers.Assumptions on the effect of pacemaker therapy affordability were limited.QoL increases were not compared to an age and gender-matched control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sr Clinical Research Program Manager</name_or_title>
      <organization>Medtronic</organization>
      <phone>+1 (651) 308 3608</phone>
      <email>jennifer.tinsley@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

